We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2051
Ocular Therapeutix
OCUL
$1.66B
| $19 | ﹤0.01% |
2
| – | – |
2024 Q1
5 quarters
|
|
2052
Cogent Biosciences
COGT
$5.38B
| $14 | ﹤0.01% |
2
| – | – |
2024 Q2
4 quarters
|
|
2053
Safe Bulkers
SB
$971M
| $7 | ﹤0.01% |
2
| – | – |
2024 Q2
4 quarters
|
|
2054
Archer Aviation
ACHR
$3.82B
| – | – |
-2,732
| Closed | -$19.4K | – |
|
2055
Advantage Solutions
ADV
$388M
| – | – |
-317
| Closed | -$12K | – |
|
2056
Aehr Test Systems
AEHR
$2.76B
| – | – |
-154
| Closed | -$1.12K | – |
|
2057
Agenus
AGEN
$346M
| – | – |
-265
| Closed | -$399 | – |
|
2058
Aldeyra Therapeutics
ALDX
$55.3M
| – | – |
-551,091
| Closed | -$3.17M | – |
|
2059
DELISTED
Allakos
ALLK
| – | – |
-1,045
| Closed | -$238 | – |
|
2060
Allogene Therapeutics
ALLO
$504M
| – | – |
-11,828
| Closed | -$17.3K | – |
|
2061
Amplify Energy
AMPY
$185M
| – | – |
-115,995
| Closed | -$434K | – |
|
2062
AMERISAFE
AMSF
$452M
| – | – |
-209
| Closed | -$11K | – |
|
2063
Global X MSCI Argentina ETF
ARGT
$712M
| – | – |
-4,665
| Closed | -$377K | – |
|
2064
AdvanSix
ASIX
$438M
| – | – |
-26
| Closed | -$589 | – |
|
2065
LeonaBio Inc
LONA
$54.2M
| – | – |
-83
| Closed | -$237 | – |
|
2066
Axogen
AXGN
$2.12B
| – | – |
-92
| Closed | -$1.7K | – |
|
2067
AMREP Corp
AXR
$110M
| – | – |
-10
| Closed | -$201 | – |
|
2068
AXT Inc
AXTI
$4.49B
| – | – |
-306
| Closed | -$431 | – |
|
2069
DELISTED
BIOATLA INC
BCAB
| – | – |
-41
| Closed | -$703 | – |
|
2070
Biohaven
BHVN
$1.82B
| – | – |
-12,923
| Closed | -$311K | – |
|
2071
Blend Labs
BLND
$236M
| – | – |
-1,409
| Closed | -$4.72K | – |
|
2072
Boot Barn
BOOT
$3.63B
| – | – |
-4,567
| Closed | -$491K | – |
|
2073
DELISTED
Berry Corp
BRY
| – | – |
-330
| Closed | -$1.06K | – |
|
2074
DELISTED
BioXcel Therapeutics
BTAI
| – | – |
-237
| Closed | -$481 | – |
|
2075
DELISTED
Carisma Therapeutics
CARM
| – | – |
-5,629
| Closed | -$1.75K | – |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.